Axtell S S, Ludwig E, Lope-Candales P
Department of Pharmacy at The Buffalo General Hospital, State University of New York at Buffalo, New York 14203, USA.
Clin Cardiol. 2001 Feb;24(2):114-8. doi: 10.1002/clc.4960240204.
The most recent published guidelines regarding management of patients surviving an acute myocardial infarction (AMI) advocate the administration of aspirin (ASA), beta blockers (BB), and angiotensin-converting enzyme inhibitors (ACEi) and discourages the use of calcium-channel blockers (CCB). Previous data collected in our region from the National Registry (NR) showed a dismal compliance with these guidelines. In an attempt to increase physician awareness and to optimize implementation of recommended guidelines, a cardiac and pharmacy steering committee was created.
The pharmacist assigned to the project identified all patients admitted with an AMI using troponin-I and creatine kinase-MB (CK-MB) reports. The pharmacist then contacted physicians to make recommendations if an adjunctive medication was not prescribed for a patient with no apparent contraindications. Administration rates for ASA, BB, ACEi, and CCB were then assessed and compared with the previously obtained baseline data from the NR.
At admission, the use of ASA increased from 70 to 72%, BB from 45 to 72%, and ACEi from 12 to 44%. In terms of medications at discharge, ASA use increased from 74 to 88%, BB from 55 to 76%, and ACEi from 30 to 40%. In addition, the prescription rates for CCB at discharge decreased from 36 to 21%.
An interdisciplinary approach for disease management is an effective method for improving adherence to treatment guidelines simply with pharmacy intervention. The percentage of patients receiving the recommended adjunctive medications increased significantly. We propose that these guidelines should be periodically inserviced to physicians. Furthermore, patient counseling sessions should also be instituted to help reinforce the importance of compliance with the medications after discharge, as well as lipid management and smoking cessation.
关于急性心肌梗死(AMI)存活患者管理的最新发布指南提倡使用阿司匹林(ASA)、β受体阻滞剂(BB)和血管紧张素转换酶抑制剂(ACEi),并不鼓励使用钙通道阻滞剂(CCB)。我们地区从国家登记处(NR)收集的先前数据显示,对这些指南的依从性很差。为了提高医生的认识并优化推荐指南的实施,成立了一个心脏和药学指导委员会。
负责该项目的药剂师使用肌钙蛋白-I和肌酸激酶-MB(CK-MB)报告确定所有因AMI入院的患者。然后,如果没有明显禁忌症的患者未开具辅助药物,药剂师会联系医生并提出建议。然后评估ASA、BB、ACEi和CCB的用药率,并与之前从NR获得的基线数据进行比较。
入院时,ASA的使用率从70%提高到72%,BB从45%提高到72%,ACEi从12%提高到44%。出院时用药方面,ASA的使用率从74%提高到88%,BB从55%提高到76%,ACEi从30%提高到40%。此外,出院时CCB的处方率从36%降至21%。
疾病管理的跨学科方法是一种仅通过药学干预提高对治疗指南依从性的有效方法。接受推荐辅助药物治疗的患者比例显著增加。我们建议应定期为医生提供这些指南的在职培训。此外,还应开展患者咨询会议,以帮助强化出院后遵医嘱用药的重要性,以及血脂管理和戒烟。